Compare · AZN vs TMBR
AZN vs TMBR
Side-by-side comparison of AstraZeneca PLC (AZN) and Timber Pharmaceuticals Inc. (TMBR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and TMBR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $263.10B, about 13843.6x TMBR ($19.0M).
- AZN has hit the wire 13 times in the past 4 weeks while TMBR has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 0 for TMBR).
- Company
- AstraZeneca PLC
- Timber Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $263.10B
- $19.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- 2026
- 2015
- News (4w)
- 13
- 0
- Recent ratings
- 25
- 0
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Timber Pharmaceuticals Inc.
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical dermatology company, focused on the development and commercialization of treatments for orphan dermatologic diseases. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
- Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
- SVP, Group Controller Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,267 units (SEC Form 4)
Latest TMBR
- Timber Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- Timber Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Bankruptcy or Receivership
- Timber Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Timber Pharmaceuticals Reveals Commencement Of NYSE American Delisting Proceedings: Common Stock Expected To Begin Trading On OTC Market
- Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market
- SEC Form 25-NSE filed by Timber Pharmaceuticals Inc.
- Timber Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Timber Pharmaceuticals Receives Court Approval Of All "First Day" Motions To Support Business Operations & Discloses Communication From NYSE American
- Timber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE American
- Timber Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Termination of a Material Definitive Agreement, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits